INTEGRATED BIOPHARMA INC

Form S-3/A April 17, 2008

As filed with the Securities and Exchange Commission on April 17, 2008

Registration No. 333-149855

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 2 to

FORM S-3 REGISTRATION STATEMENT

Under the Securities Act of 1933

Integrated BioPharma, Inc.

(Exact name of Registrant as specified in its charter)

Delaware283422-2407475(State or other jurisdiction of(Primary standard industrial(I.R.S. employer
Identification no.)

incorporation or organization) Classification code number)

225 Long Avenue Hillside, NJ 07205 (888) 319-6962

(Address, including zip code, and telephone number, including area code, of Registrant s principal executive offices)

E. Gerald Kay Chief Executive Officer Integrated BioPharma, Inc. 225 Long Avenue Hillside, NJ 07205 (888) 319-6962

(Address, including zip code, and telephone number including area code, of agent for service)

Copies to:
Andrew H. Abramowitz, Esq.
Greenberg Traurig, LLP
200 Park Avenue
New York, NY 10166

Telephone (212) 801-9200

Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. []

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. []

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. []

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. []

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. []

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. []

CALCULATION OF REGISTRATION FEE

		Proposed	Proposed	
		Maximum	Maximum	Amount of
Title of Each Class of Securities to be	Amount to be	Offering Price	Aggregate Offering	Registration
Registered	Registered	Per Share (1)	Price (1)	Fee (2)
Common Stock, \$0.002 par value per	6,003,167	\$2.92	\$17,529,247	\$688.90
share				

- (1) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) of the Securities Act of 1933, based on the average of the high and low sales prices of the common stock, as reported on the NASDAQ Global Market on March 19, 2008.
- (2) Previously paid.

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

EXPLANATORY NOTE

This Amendment is filed solely to file an amendment to Item 16 of Part II. No change is made to the preliminary prospectus constituting Part I of this Registration Statement or Items 14, 15 or 17 of Part II of the Registration Statement.

PART II INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits.

Exhibit Number

5.1 Opinion of Greenberg Traurig, LLP, counsel to the registrant*

23.1 Consent of Independent Registered Public Accounting Firm

23.2 Consent of Greenberg Traurig, LLP (contained in Exhibit 5.1)*

24.1 Power of attorney*

^{*} previously filed

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hillside, State of New Jersey, on this 17th day of April 2008.

INTEGRATED BIOPHARMA, INC. By: /s/ E. Gerald Kay
E. Gerald Kay
Chief Executive Officer

(principal executive officer)

By: /s/ Dina L. Masi
Dina L. Masi
Chief Financial Officer
(principal accounting and financial officer)

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated

/s/ E. Gerald Kay E. Gerald Kay	Chairman and Chief Executive Officer (Principal Executive Officer)	April 17, 2008
/s/ Dina L. Masi Dina L. Masi	Chief Financial Officer (Principal Accounting and Financial Officer)	April 17, 2008
* Carl DeSantis	Director	April 17, 2008
* Riva Sheppard	Director	April 17, 2008
* Christina Kay	Director	April 17, 2008
* Robert B. Kay	Director	April 17, 2008
* Robert Canarick	Director	April 17, 2008
* Glenn Chang	Director	April 17, 2008
Vidadi M. Yusibov	Director	
* By: /s/ Dina L. Masi Dina L. Masi Attorney-in-fact		

EXHIBIT INDEX

Exhibit Number

- 5.1 Opinion of Greenberg Traurig, LLP, counsel to the registrant*
- 23.1 Consent of Independent Registered Public Accounting Firm
- 23.2 Consent of Greenberg Traurig, LLP (contained in Exhibit 5.1)*
- 24.1 Power of attorney*

^{*} previously filed